Saturday, January 24, 2015 5:15:04 PM
Yes Ebolacide testing is a wild card. But it's a wild card that could send the price crashing down as easily as it could cause the price to spike up. Most people here seem near certain that Ebolacide2 will work. I'm not so sure the optimism is warranted. The first version of Ebolacide didn't cure any mice. Now they say we understand the virus better, and know the right receptor to use. Well, maybe. Or maybe there's more about the Ebola virus that we still don't know.
I think the major reason Zincfinger dumped his stock and switched from bull to bear, aside from the usual interminable delays, was the choice by NNVC management to focus on Ebolacide. He saw that as trading a near sure thing (Flucide development) for a high risk gamble on Ebolacide. I agree -- it is still the case that more people get killed by influenza than by Ebola, and the right thing to do would have been to concentrate on Flucide. NNVC has too many pots on the stove for such a small company, and is taking a bit risk on Ebolacide. Suppose it doesn't work -- NNVC will just continue with Flucide, right? Except we know that some time before phase 2 trials NNVC will have to sell some of those shares on the shelf and raise some money. It will make a huge difference to current shareholders whether those shares are sold at $10 or ten times as many at $1.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM